A Long-term Safety Follow-up Study of Patients Having Received Infusions of HepaStem
Phase of Trial: Phase II
Latest Information Update: 07 Jun 2019
Price : $35 *
At a glance
- Drugs Mesenchymal stem cell therapy (Primary)
- Indications Liver disorders
- Focus Adverse reactions; First in man
- Acronyms SAF 001
- Sponsors Promethera Biosciences
- 23 May 2019 Status changed from active, no longer recruiting to completed.
- 07 Feb 2018 This trial has been completed in Italy according to European Clinical Trials Database record.
- 21 Sep 2017 This trial has been completed in Belgium.